Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIPP study of sunitinib in recurrent or metastatic paraganglioma/pheochromocytoma
NL-OMON37490Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in Paraganglioma (PGL) and pheochromocytoma, sponsored by University Medical Center Groningen. Primary endpoint: Clinical benefit rate. Started Jul 2012; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
Paraganglioma (PGL)pheochromocytoma
Beyond the preview
Go deeper on NL-OMON37490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37490.